ARTICLE | Distillery Therapeutics
Therapeutics: Mammalian target of rapamycin (mTOR; FRAP; RAFT1); interleukin-8 (IL-8; CXCL8)
September 15, 2016 7:00 AM UTC
Cell culture studies suggest combining doxorubicin with mTOR inhibitors could help treat hepatocellular carcinoma (HCC). In a xenograft mouse model of HCC, the generic chemotherapy doxorubicin and the...